| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/01/2009 | CN101396554A Use of recombined human interferon gamma in preparing antiviral medicine |
| 04/01/2009 | CN101396553A Recombined human blood vessel endothelial inhibin sustained-release injection composition |
| 04/01/2009 | CN101396378A Nano gene peptides products and preparation method and use thereof |
| 04/01/2009 | CN101396347A Preparation method of recombined human blood-vessel endothelia inhibin sustained-released microsphere |
| 04/01/2009 | CN101396341A Anti-cancer sustained-released agent |
| 04/01/2009 | CN100473721C Pneumovirus NS proteins antagonising interferon (IFN) response |
| 04/01/2009 | CN100473663C Heterologous expression of neisserial proteins |
| 04/01/2009 | CN100473662C Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure |
| 04/01/2009 | CN100473418C The preparation of compound digestive enzyme and preparation method thereof |
| 04/01/2009 | CN100473417C Method of modulating memory effector T-cells using CD2-binding agent, and compositions |
| 04/01/2009 | CN100473377C Process for producing soft gelatin capsule |
| 04/01/2009 | CN100473284C Additives for crustacean or fish feeds and feeds |
| 04/01/2009 | CA2605036A1 Renoprotection by growth hormone-releasing hormone and agonists |
| 03/31/2009 | US7511131 Antisense modulation of apolipoprotein B expression |
| 03/31/2009 | US7511122 Monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal; light and heavy chains comprising complementarity determining regions |
| 03/31/2009 | US7511121 Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors |
| 03/31/2009 | US7511120 Granulocyte colony stimulating factor obtained from eggs laid by transgenic avians having newly described G-CSF glycosylation patterns; gene expression of exogenous proteins |
| 03/31/2009 | US7511119 PRAME peptide analogues |
| 03/31/2009 | US7511118 Analogs of peptides corresponding to class I major histocompatibility complex (MHC)-restricted T-cell epitopes that contain amino acid substitutions of norleucine and/or norvaline; intranodal administration a an immunopotentiating agent |
| 03/31/2009 | US7511094 2-methylbutyraldehyde diethyl acetal end capped polyoxyethylene glycol; polyalkylene oxide, polyivnylpyrrolidone, polyvinyl alcohol, polyoxazoline etc. endcapped with polyetherpolyamine copolymers or oligomers covalently attached to diacetal tetramethylene group |
| 03/31/2009 | US7511051 Cidofovir peptide conjugates as prodrugs |
| 03/31/2009 | US7511039 Thrombin inhibitors; protease inhibition, kinase inhibition, CAAX inhibition, interference with peptides binding to SH2 domains and inhibition of MCH-I and/or MHC II presentation of peptides to T cell receptors |
| 03/31/2009 | US7511037 N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor |
| 03/31/2009 | US7511027 Administering a nucleoside or a nucleoside analog, such as (5'-fluoro-5-methyl-beta-arabinofuranosyl-uridine) or salt or prodrug that suppresses the expression of hepatitis B surface or preS1 antigen in the host 100-fold |
| 03/31/2009 | US7511024 Factor VII or VIIA-like molecules |
| 03/31/2009 | US7511019 Method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels in a human patient in need of treatment for coronary artery disease an effective amount of a recombinant fibroblast |
| 03/31/2009 | US7511018 Juvenile hemochromatosis gene (HFE2A) cleavage products and uses thereof |
| 03/31/2009 | US7511017 Inhibiting apoptosis associated with HIV infection; immunoglobulin constant domain heterologous polypeptide; isolated nucleic acid encoding a human polypeptide, tumor necrosis factor receptor-5 |
| 03/31/2009 | US7511016 Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof |
| 03/31/2009 | US7511015 Ribosylated human neutrophil peptide-1or an ADP-ribosylated human neutrophil peptide-1; modified antimicrobial activity compared to alpha defensin lacking ADP-ribosylated or ribosylated residue; altered chemotaxis of T cells, altered neutrophil recruitment |
| 03/31/2009 | US7511014 Cyclosporin active, fatty acid triglyceride, glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10; immunosuppressant, anti inflammatory, anti parasitic |
| 03/31/2009 | US7511013 Cyclosporin analogues and their pharmaceutical uses |
| 03/31/2009 | US7511012 Myostatin binding agents |
| 03/31/2009 | US7511011 Synthetic lipid mixtures for the preparation of a reconstituted surfactant |
| 03/31/2009 | US7511010 Pharmaceutical or cosmetic composition and use of a PKC inhibitor with an MMP inhibitor for inhibiting Langerhans' cell migration |
| 03/31/2009 | US7511009 Recombinant DNA of a gene having a DNA sequence or amino acid sequence; antitumor agents |
| 03/31/2009 | US7510875 Methods for producing purified adenoviral vectors |
| 03/31/2009 | US7510867 Expression may be controlled by a regulatory element along with a small polyadenylation signal; entire gene expression cassettes may be packaged into a viral vector, preferably an adeno-associated virus vector; five or six rod repeats; cysteine-rich domain; muscular dystrophy |
| 03/31/2009 | US7510862 Nucleic acid comprising retroviral sequences for use as tools in generation of vaccines for prevention of viral diseases and infection; immunotherapy; viricides, antisense agents |
| 03/31/2009 | US7510855 Comprises nucleotide sequences coding protein of urogenital system for identifying moduators for treatment of cell proliferative and metastatic disorders |
| 03/31/2009 | US7510853 Exhibiting similarity to cytokine; isolated or recombinant polynucleotide encoding antigenic polypeptide of sequence 2 |
| 03/31/2009 | US7510847 Drug screening for compound having uricosuric regulating action by incubating a transformed cell expressing a recombinant protein with uric acid; and determining an uptake of uric acid; gout |
| 03/31/2009 | US7510845 Using g protein coupled receptor to identifying modulator for use in treatment and prevention of pain; antinociceptive agents |
| 03/31/2009 | US7510843 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease |
| 03/31/2009 | US7510830 Cancer treatment by combination therapy |
| 03/31/2009 | US7510828 Therapy, prevention of viral infections; obtaining viron sample; incubation, monitoring, calibration: using antithrombin agent |
| 03/31/2009 | US7510824 Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| 03/31/2009 | US7510732 Analgesic and anti-inflammatory composition |
| 03/31/2009 | US7510720 Producing a passive immunity vaccine against Sarcocystis neurona by providing Sarcocystis neurona 16 kDa and 30 kDa antigens as determined by SDS polyacrylamide gel electrophoresis;immunizing mammal in mixture with adjuvant; removing serum; isolating antibodies; administering antibodies |
| 03/31/2009 | US7510714 Administering a plasminogen activator inhibitor type 1 isoform lacking a reactive center loop and lacking a heparin-binding domain so that angiogenesis is decreased; blocking release of endothelial growth factors (VEGF) from a VEGF-heparin complex; inducing angiostatin formation; antiplaque agents |
| 03/31/2009 | US7510711 Nucleotide sequence coding monoclonal antibody; anticancer agents; antiinflammatory agents; immunology disorders |
| 03/31/2009 | US7510707 PAR, a novel marker gene for breast and prostate cancers |
| 03/31/2009 | US7510700 Pathological tissue detection and treatment employing targeted benzoindole optical agents |
| 03/31/2009 | CA2494888C Substances for preventing and treating autoimmune diseases |
| 03/31/2009 | CA2192467C Calcium binding recombinant antibody against protein c |
| 03/31/2009 | CA2066204C Cystic fibrosis gene |
| 03/28/2009 | CA2640655A1 Anaplastic lymphoma kinase (alk) as oncoantigen for lymphoma vaccination |
| 03/26/2009 | WO2009039409A1 Targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| 03/26/2009 | WO2009039368A1 Prevention of infarct expansion |
| 03/26/2009 | WO2009039361A2 Process for the preparation of (s)-2-(3-tert-butylureido)-3,3-dimethylbutanoic acid |
| 03/26/2009 | WO2009039310A2 Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment |
| 03/26/2009 | WO2009039217A1 Medicaments for the treatment of coronary syndromes |
| 03/26/2009 | WO2009039188A1 Peptides and methods for the treatment of gliomas and other cancers |
| 03/26/2009 | WO2009038880A1 Novel e-selectin variant |
| 03/26/2009 | WO2009038745A1 Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| 03/26/2009 | WO2009038689A2 Compositions and methods for diagnosis and treatment of type 2 diabetes |
| 03/26/2009 | WO2009038458A1 Nutritional formulation with high energy content |
| 03/26/2009 | WO2009038243A1 Composition for treating retinopathy or glaucoma comprising thrombin derived peptides |
| 03/26/2009 | WO2009038106A1 Oral administration drug containing alanyltyrosine |
| 03/26/2009 | WO2009038026A1 Ctl inducer composition |
| 03/26/2009 | WO2009037264A2 Colonic delivery of antimicrobial agents |
| 03/26/2009 | WO2009037191A2 Use of g-csf for the treatment of stroke |
| 03/26/2009 | WO2009037061A2 Use of hydrophobin polypeptides as penetration enhancers |
| 03/26/2009 | WO2009036997A1 Truncated secretory aspartyl proteinase 2 |
| 03/26/2009 | WO2009036568A1 Methods and compositions for treating tumors and viral infections |
| 03/26/2009 | WO2009036510A1 Novel avian cytokines and genetic sequences encoding same |
| 03/26/2009 | WO2009018643A3 Use of pharmaceutical compound containing crotoxin for the treatment of muscle dystonias |
| 03/26/2009 | WO2009011795A3 Methods for treating stress induced emotional disorders |
| 03/26/2009 | WO2009010874A3 Preprocalcitonin antigen t epitopes |
| 03/26/2009 | WO2009003732A3 Peptides with high affinity for the prolactin receptor |
| 03/26/2009 | WO2008151235A3 Compositions for delivering medicaments into the lungs, uses thereof |
| 03/26/2009 | WO2008151119A3 Compositions and methods for use of scar tissue in repair of weight bearing surfaces |
| 03/26/2009 | WO2008137780A3 Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases |
| 03/26/2009 | WO2008137633A3 Methods of modulating cellular homeostatic pathways and cellular survival |
| 03/26/2009 | WO2008132155A3 Inhibitors of the binding between hdm2 and the proteasome |
| 03/26/2009 | WO2008121437A3 Trophinin-binding peptides and uses thereof |
| 03/26/2009 | WO2008118148A3 Adiponectin for the treatment and diagnosis of albuminuria |
| 03/26/2009 | WO2008076819A3 Human growth hormone formulations |
| 03/26/2009 | WO2008039525A3 Cadherin antagonists in combination with anticancer agents for use in cancer treatment |
| 03/26/2009 | WO2007146132A3 Prevention of hiv infection |
| 03/26/2009 | WO2005077046A3 A composition and method of treating mastitis |
| 03/26/2009 | WO2005076972A3 Chimeric vegf peptides |
| 03/26/2009 | WO2005017096A3 SPLICE VARIANTS OF ErbB LIGANDS, COMPOSITIONS AND USES THEREOF |
| 03/26/2009 | WO2005014615A3 Self-assembling peptides incorporating modifications and methods of use thereof |
| 03/26/2009 | WO2004093804A3 Human polypeptides encoded by polynucleotides and methods of their use |
| 03/26/2009 | WO2004087733A3 Prevention and treatment of alzheimer amyloid deposition |
| 03/26/2009 | WO2004080387A3 Immunogenic cd19 ligand-antigenic molecule complexes and fusion proteins |
| 03/26/2009 | WO2003070158A3 Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases |
| 03/26/2009 | US20090082713 Method of enhancing iontophoretic delivery of a peptide |
| 03/26/2009 | US20090082566 Di- and tri-peptide mono- and di-esters of acyclovir and gancyclovir and derivatives; esters have sufficient hydrophilicity to be formulated into pharmacologically active compositions such as aqueous solutions, eye drops; treating herpes simplex types 1, 2, varicella zoster virus, human cytomegalovirus |